The FEND-TB consortium will be led by a dynamic team of expert investigators with decades of experience in the conduct of multicenter, multidisciplinary international research programs and diagnostic evaluation programs on TB.
Jerrold Ellner, MD (PI)
Susan Dorman, MD (Co-PI & Clinical Director)
David Alland, MD (Co-PI & Scientific Director)
The program will be enhanced by a small and responsive Leadership Committee and an Executive Committee with representation across the consortium. Several cores and committees represent the service lines of the FEND-TB program. The FEND-TB leadership is comprised of leading innovators in their respective TB fields. Many have collaborated together for over a decade, discovering TB biomarkers, developing infectious disease diagnostics, modeling diagnostic impact; and most importantly, leading innovative high-quality clinical studies.
Dr. Ellner has led multidisciplinary observational cohort programs at international sites comparable in scope to FEND-TB including currently TBRU, RePORT India and RePORT South Africa. Dr. Alland is internationally recognized for his contributions to TB diagnostic research and understanding of mechanisms of drug resistance. Dr. Dorman has been PI on sentinel studies of TB diagnostics including currently a large RO1 for further study of Xpert Ultra as well as clinical trials of new treatments including a multicenter trial of rifapentine for treatment shortening. Dr. Ellner was PI, Dr. Dorman Clinical Director and Dr. Alland Scientific Director of the NIAID TB-Clinical Diagnostics Research Consortium (TB-CDRC) from 2009-2016.